Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$1.83
EPS est.
$1.45
EPS surprise
+26.21%
1-day move
+7.86%
Krystal Biotech reported strong earnings with an EPS of $1.83, exceeding expectations significantly. The stock reacted positively, rising by 7.86%. However, there was no revenue reported or guidance provided, leaving some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.83 | N/A | +26.21% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for patients with rare diseases. Operating in the health care sector, it aims to address unmet medical needs through innovative treatments, which is increasingly important as the demand for advanced medical solutions grows.
Last quarter
In the last quarter, Krystal Biotech reported an EPS of $1.70, exceeding estimates by nearly 5%. The stock reacted positively, gaining over 4% the following day.
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+23.73%
Avg 1-day reaction
-1.88%
Overall, there is cautious optimism surrounding Krystal Biotech's upcoming earnings report, especially given its recent performance. Investors are eager to see if the company can maintain its positive momentum.
Bull case
If Krystal Biotech continues to beat EPS estimates and shows strong revenue growth, it could lead to increased investor confidence and a higher stock price.
Bear case
Conversely, if the company misses expectations or fails to provide clear guidance on future growth, it could lead to a significant drop in stock price.
The print will turn on these.
Q1
What will the EPS be for Q1-2026?
EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.
Q2
How are R&D expenses trending in relation to revenue growth?
Understanding the balance between R&D spending and revenue growth will provide insights into the company's future prospects and sustainability.
—
Est. EPS
$0.25
Est. Rev
$156M
Impl. Move
±16.1%
Why consensus could be wrong
The Street may be underestimating Krystal Biotech's potential for strong EPS growth due to recent advancements in their pipeline that have not been fully factored into earnings expectations.
Supporting evidence
Krystal has consistently beaten EPS estimates in recent quarters, suggesting a trend of stronger-than-expected performance.
The options market is pricing in a larger move than historical averages, indicating heightened expectations that could be justified by recent developments.
Key risk
If the EPS comes in above $1.80, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Krystal Biotech can sustain its recent growth trajectory, making EPS a focal point for this quarter.
Bull confirmed if
An EPS of $1.80 or higher would confirm the bullish case, indicating strong profitability.
Bear confirmed if
An EPS below $1.50 would support the bearish case, suggesting potential issues with profitability.
What the market is pricing for the move.
Implied Move
±9.51%
Historical Avg
±8.0%
The options market is pricing in a potential move of about 9.5%, indicating that traders expect some volatility around the earnings announcement.
Options are pricing ±9.8% while KRYS has averaged ±8.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
31.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Krystal Biotech beats expectations, history suggests a potential stock increase of around 1.55%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.
Miss
A miss could lead to a decline in stock price, with historical patterns indicating an average drop of about 10.23%.
The lines on the call that would change the story.